Analysis: Sagility India Limited

Growth thesis

Sagility India is a healthcare operations specialist serving U.S. payers and providers, with payer work at 89.9% of Q2 FY27 revenue and provider work at 10.1%. The business runs claims, enrollment, member and provider engagement, clinical utilisation, payment integrity and revenue cycle operations. It is not a generic BPM scale game: the value comes from domain depth, long incumbency and the ability to take accountability for workflows rather than sell seats. Q2 FY27 revenue was ₹20,321 million ($212.6 million), up 22.5% year-on-year in INR and 12.2% in constant currency; adjusted EBITDA was ₹5,353 million at a 26.3% margin, the highest in six quarters. H1 FY27 revenue was ₹39,956 million, up 25% in INR and 13.7% in constant currency, with a 25.2% adjusted EBITDA margin.

The economics are supported by recurring operations work and high switching costs. Sagility had 105 active client groups at Q2 FY27, and all top 10 client groups now generate more than $20 million on a trailing 12-month basis. The top five clients average 18 years of tenure. Management estimates payer outsourcing penetration in the low 20s, so most addressable work is still in-house. That is the structural opportunity: clients under medical loss ratio pressure need administrative and clinical cost taken out, and an incumbent with domain knowledge can absorb work that a generalist cannot. The counterweight is concentration. The top 10 clients were 83.92% of FY26 revenue, and while that is down from 90.53% in FY25, the largest relationships still dominate the earnings base.

The near-term earnings path is guided, not inferred. FY27 revenue guidance is low double-digit organic growth in constant currency; management reiterated it in October 2026 even though OE/AEP seasonal revenue is expected slightly lower than last year, about 100 basis points lower as a share. FY27 adjusted EBITDA margin guidance was raised to 25-26% from 24-25%, after Q2 absorbed the full-quarter statutory wage impact of about $148 million versus $70 million in Q1. The guidance is credible against Q2, but it is not a structural margin upgrade. Management still points to a 24-26% long-term range, with only potential marginal improvement if Sagility retains some AI-driven productivity gains. A large part of AI benefits is expected to pass to clients, and prior disclosure put AI-related revenue cannibalization at roughly 2% for FY27.

The acquisition strategy is now part of the earnings path. CareSeed, closed June 2026, is integrated into clinical practice and adds HEDIS reporting and chart abstraction through Forecast and Harvest, plus 26 new mid-market payer clients. Each of those clients currently generates under $1 million, and management has said large clients already have established quality-reporting vendors, so the platform play is mainly mid-market. Chiroc Health LLC, closed October 2026, is more material to provider capability. It adds clinical documentation improvement, medical coding, risk adjustment and HEDIS quality, with $13 million trailing 12-month revenue to September 2026 at a 35.8% adjusted EBITDA margin and 115% net revenue retention. Sagility paid $20 million upfront with up to $12.35 million earnout tied to CY27-CY28 revenue targets. Management said there are no common clients, so cross-sell must create new relationships. It also said the deal is for revenue synergies, not margin improvement. No explicit multi-year provider revenue target was given.

Capital allocation is a genuine positive. Sagility moved from net debt of ₹1,962 million at FY26 end to net cash of ₹1,127 million at September 2026. H1 FY27 operating cash flow was ₹6,343 million and free cash flow ₹5,176 million. The board approved a ₹0.15 interim dividend. Management said it remains on track to repay outstanding debt fully during FY27, though the Q2 transcript says '2023' and the date remains unresolved. The stronger balance sheet gives capacity for further capability acquisitions without new equity, but it does not by itself prove that the next acquisition will earn a return.

Management delivery is mixed but generally credible. FY26 guidance was raised twice and beaten: revenue grew 23.6% in constant currency and adjusted EBITDA margin was 25.3%. FY27 margin guidance has now been raised once. FY27 revenue guidance is still open. BroadPath cross-sell remains the soft spot: one disclosed win in FY26, then six or seven active opportunities in July 2026, with no new named win in Q2 FY27. Chiroc and CareSeed add new cross-sell pools, but neither has a disclosed revenue conversion yet.

The thesis is a compounder only if three things hold. First, organic constant-currency growth must stay at or above the low double-digit guide as OE/AEP seasonal revenue normalizes lower; Q2's 11.9% leaves a thinner buffer than Q1. Second, the raised 25-26% FY27 margin must hold as the full wage impact stays in the run-rate; the long-term 24-26% range limits structural expansion. Third, acquired capability must convert into revenue: CareSeed into mid-market quality work, Chiroc into provider mid-cycle RCM, and BroadPath into broader payer services. The falsifiers are clear: organic growth below low double digits, FY27 margin below 25%, no named Chiroc or BroadPath cross-sell wins, or a return to net debt without a matching earnings contribution.

Why is Sagility India Limited stock rising?

• Q2 FY27 adjusted EBITDA was ₹5,353 million at a 26.3% margin, the highest in six quarters, despite the full-quarter statutory wage impact. Management raised FY27 adjusted EBITDA margin guidance to 25-26% from 24-25%, citing operating leverage, cost discipline, delivery efficiencies and favourable FX. The guidance raise shows the wage headwind is being absorbed rather than deferred.
• Q2 FY27 organic constant-currency growth was 11.9%, after 14.9% in Q1 FY27, and H1 FY27 constant-currency growth was 13.7%. Management reiterated low double-digit organic constant-currency growth for FY27 even while expecting OE/AEP seasonal revenue to be slightly lower than last year. The buffer is thinner than in Q1, but the guidance is being held with less seasonal support.
• Chiroc Health LLC closed in October 2026, adding clinical documentation improvement, medical coding, risk adjustment and HEDIS quality for health systems, physician groups and value-based care organisations. It reported $13 million trailing 12-month revenue to September 2026 at a 35.8% adjusted EBITDA margin, 115% net revenue retention and 750 employees. Sagility paid $20 million upfront with up to $12.35 million earnout over CY27-CY28; the economic test is cross-selling into provider clients where management says there are no common clients.
• Q2 FY27 deal ACV rose 18.2% year-on-year to $40.2 million across 31 existing clients and one new client. Management is implementing Synchrony Claims Lifecycle for claims adjudication and Synchrony RCM Lifecycle for denials, both agentic workflows with human checkpoints. The commercial value is not the ACV alone; it is the shift from narrow process work into larger, workflow-level mandates that can carry managed-service pricing.
• Sagility moved from net debt of ₹1,962 million at FY26 end to net cash of ₹1,127 million at September 2026. H1 FY27 operating cash flow was ₹6,343 million and free cash flow ₹5,176 million. The board approved a ₹0.15 interim dividend, and management said it remains on track to repay outstanding debt fully during FY27. That balance-sheet capacity can fund acquisitions without new equity.

Research report

companyname: Sagility Limited (formerly Sagility India Limited, earlier Sagility India Private Limited) ticker: SAGILITY sector: Healthcare Business Process Management (BPM) / Healthcare Operations Services Sagility is a technology-enabled healthcare operations company that serves only the U.S. healthcare industry. It runs mission-critical administrative and clinical operations for health insurers (payers), healthcare providers, and pharmacy benefit managers: processing claims, enrolling member...

Catalysts

acquisition inorganic, debt reduction

Growth guidance

FY27: low double-digit organic revenue growth in constant currency, reiterated despite OE/AEP seasonal revenue expected slightly lower than last year. FY27 adjusted EBITDA margin guidance raised to 25-26% from 24-25%, despite the full statutory wage impact. Longer term, management continues to indicate a 24-26% adjusted EBITDA margin range, with potential marginal increase if AI benefits are retained. No FY28 company revenue or margin guidance was provided.

Management consistency

overdeliver